169 related articles for article (PubMed ID: 23247867)
1. Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.
Xue YZ; Sheng YY; Liu ZL; Wei ZQ; Cao HY; Wu YM; Lu YF; Yu LH; Li JP; Li ZS
Tumour Biol; 2013 Apr; 34(2):895-9. PubMed ID: 23247867
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
[TBL] [Abstract][Full Text] [Related]
3. Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis.
Zhao ZK; Wu WG; Chen L; Dong P; Gu J; Mu JS; Yang JH; Liu YB
Tumour Biol; 2013 Jun; 34(3):1473-7. PubMed ID: 23355337
[TBL] [Abstract][Full Text] [Related]
4. High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Gu F; Liu CY; Wang RJ; Li J; Xu JY
Tumour Biol; 2013 Apr; 34(2):853-8. PubMed ID: 23242609
[TBL] [Abstract][Full Text] [Related]
5. NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma.
Shi R; Wang L; Wang T; Xu J; Wang F; Xu M
Med Oncol; 2014 Mar; 31(3):852. PubMed ID: 24469954
[TBL] [Abstract][Full Text] [Related]
6. MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma.
Chen DW; Fan YF; Li J; Jiang XX
Tumour Biol; 2013 Jun; 34(3):1553-7. PubMed ID: 23400716
[TBL] [Abstract][Full Text] [Related]
7. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Tbx3 predicts poor prognosis of patients with resectable pancreatic carcinoma.
Wang HC; Meng QC; Shan ZZ; Yuan Z; Huang XY
Asian Pac J Cancer Prev; 2015; 16(4):1397-401. PubMed ID: 25743805
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific membrane antigen as a marker of pancreatic cancer cells.
Ren H; Zhang H; Wang X; Liu J; Yuan Z; Hao J
Med Oncol; 2014 Mar; 31(3):857. PubMed ID: 24477651
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma.
Zhang J; Jiang X; Zhang J
World J Surg Oncol; 2014 Mar; 12():49. PubMed ID: 24581082
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer.
Song Z; Ren H; Gao S; Zhao X; Zhang H; Hao J
Tumour Biol; 2014 Nov; 35(11):11319-28. PubMed ID: 25119596
[TBL] [Abstract][Full Text] [Related]
13. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
14. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
15. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Gu F; Ma N; Zhang L; Bian JM; Cao HY
Tumour Biol; 2013 Aug; 34(4):2309-13. PubMed ID: 23568706
[TBL] [Abstract][Full Text] [Related]
16. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).
Radulović P; Krušlin B
Bosn J Basic Med Sci; 2018 Aug; 18(3):246-251. PubMed ID: 29924959
[TBL] [Abstract][Full Text] [Related]
18. Expression of NEDD9 in hepatocellular carcinoma and its clinical significance.
Lu P; Wang ZP; Dang Z; Zheng ZG; Li X; Zhou L; Ding R; Yue SQ; Dou KF
Oncol Rep; 2015 May; 33(5):2375-83. PubMed ID: 25812772
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
[TBL] [Abstract][Full Text] [Related]
20. DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.
Xue YZ; Wu TL; Wu YM; Sheng YY; Wei ZQ; Lu YF; Yu LH; Li JP; Li ZS
Tumour Biol; 2013 Oct; 34(5):2857-61. PubMed ID: 23681804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
